HomeLarge Type Edition
HOME ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Services
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
PubMed
Right arrow PubMed Citation
The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 61:1039-1047 (2006)
© 2006 The Gerontological Society of America

Effect of Aging on Bone Marrow-Derived Murine CD11c+CD4CD8{alpha} Dendritic Cell Function

Annabelle Grolleau-Julius, Monika R. Garg, RuRan Mo, Lloyd L. Stoolman and Raymond L. Yung

1 Divisions of Geriatric Medicine and Rheumatology, Department of Internal Medicine, and 2 Department of Pathology, University of Michigan, Ann Arbor.
3 GRECC, Ann Arbor Veteran Affairs Medical Center, Michigan.

Address correspondence to Raymond L. Yung, MD, Room 5312 CCGC, 1500 East Medical Center Drive, Ann Arbor, Michigan, 48109-0940. E-mail: ryung{at}umich.edu

Dendritic cells (DCs) are actively used as cellular adjuvant in cancer immunotherapy. However, although DC immunotherapies primarily target the elderly population, little is known about the effect of aging on DC functions. Here, we compared the T-cell stimulation, cytokine production, and tumor surveillance functions of bone marrow-derived CD11c+CD4CD8{alpha} DCs of old and young C57BL/6 mice. Old immature bone marrow-derived CD4CD8{alpha} DCs (imDCs) were 4 times less effective than were young DCs in stimulating syngeneic CD4+ T-cell proliferation. Old imDCs also have decreased DC-specific/intracellular adhesion molecule type 3-grabbing, nonintegrin (DC-SIGN) expression compared to young DCs. Interestingly, mice treated with the ovalbumin peptide-pulsed young DCs exhibited significantly greater tumor regression than with ovalbumin peptide-pulsed old DCs. Old terminally differentiated bone marrow-derived DCs (tDC) also have increased interleukin-10, but decreased interleukin-6 and tumor necrosis factor-{alpha} production. Taken together, these results have important implications in the clinical application of DC-based tumor immunotherapy in elderly persons.




This article has been cited by other articles:


Home page
Cancer Res.Home page
A. Grolleau-Julius, E. K. Harning, L. M. Abernathy, and R. L. Yung
Impaired Dendritic Cell Function in Aging Leads to Defective Antitumor Immunity
Cancer Res., August 1, 2008; 68(15): 6341 - 6349.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. Agrawal, S. Agrawal, J.-N. Cao, H. Su, K. Osann, and S. Gupta
Altered Innate Immune Functioning of Dendritic Cells in Elderly Humans: A Role of Phosphoinositide 3-Kinase-Signaling Pathway
J. Immunol., June 1, 2007; 178(11): 6912 - 6922.
[Abstract] [Full Text] [PDF]




HOME ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by The Gerontological Society of America.